GADD45 deregulation in cancer: frequently methylated tumor suppressors and potential therapeutic targets.
Zerbini
Luiz F
LF
Beth Israel Deaconess Medical Center Genomics Center, Harvard Medical School, Boston, MA 02115, USA.
Libermann
Towia A
TA
D000595:Amino Acid Sequence; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D001374:Azacitidine / Q000031:analogs & derivatives / Q000494:pharmacology; D018797:Cell Cycle Proteins / Q000235:genetics*; D002460:Cell Line; D045744:Cell Line, Tumor; D018899:CpG Islands / Q000235:genetics; D019175:DNA Methylation / Q000187:drug effects; D015254:DNA Modification Methylases / Q000037:antagonists & inhibitors; D000077209:Decitabine; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008954:Models, Biological; D008969:Molecular Sequence Data; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D009687:Nuclear Proteins / Q000235:genetics*; D011379:Prognosis; D011401:Promoter Regions, Genetic / Q000235:genetics; D017386:Sequence Homology, Amino Acid; D025521:Tumor Suppressor Proteins / Q000235:genetics; D000097642:GADD45 Proteins
D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine; D018797:Cell Cycle Proteins; D015254:DNA Modification Methylases; D000077209:Decitabine; D009687:Nuclear Proteins; D025521:Tumor Suppressor Proteins; C439070:GADD45A protein, human; D000097642:GADD45 Proteins